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ORIGINAL ARTICLE
Hodgkin’s lymphoma (HL), previously called
Hodgkin’s disease, is one of the most curable
malignancies, with a cure rate near 80%.1,2 The
incidence of HL varies among different geographic
locations, and is highest in North America and
Europe and lowest in Asia.3,4 In 2002, the Inter-
national Agency for Research on Cancer (IARC)
(http://www-dep.iarc.fr/globocan/globocan.html)
estimated that the age-stratified incidence rate of
HL in males and females is 3.2 and 2.4 per
100,000, respectively, in North America, but only
0.3 and 0.1, respectively, in East Asia. However, it
remains unclear whether there are differences in
the distribution of histopathologic subtypes, clini-
cal features and treatment outcomes between HL
patients in the West and in the East because the
number of reports and the number of patients
studied are both limited.5
In Taiwan, the crude and age-adjusted rates of
HL were 0.19–0.62 and 0.21–0.60 per 100,000
per year, respectively, from the year 1979 to 2002,
compared to rates of 1.33–7.15 and 1.69–6.74,
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respectively, for non-HL during the same period,
according to the annual report of the Cancer Reg-
istry System (CRS) of the Department of Health,
Executive Yuan, Taiwan (http://crs.cph.ntu.edu.tw).
It would be of interest to know whether the clin-
ical pattern of HL differs between Taiwanese and
Western populations. Here, we report the charac-
teristics of HL in a cohort of 133 patients in a
university hospital in Taiwan and compare them
with those in Western countries. Our results may
shed light on the direction of future studies of
HL in Taiwan and other Asian countries.
Methods
Patients
From January 1985 to December 2004, 173 pa-
tients with HL, compared with 1975 patients with
non-HL in the same period, were registered in the
Cancer Registry of the Office of Medical Records,
National Taiwan University Hospital. Among
them, 24 had received initial therapy elsewhere
before being referred to this institute and 16 
refused management and were lost to follow-up
soon thereafter. The remaining 133 patients were
enrolled in this study. The clinical characteristics
and laboratory data were collected retrospectively.
HL was categorized histopathologically by the
Rye classification system.6 The disease was staged
clinically according to the Ann Arbor system.7
Bulky tumor was defined as tumor size greater
than 10 cm in diameter or widening of the medi-
astinum by greater than one third of the maximum
intrathoracic diameter on a chest radiograph.7
Twenty-three patients (17%) received COPP
chemotherapy (cyclophosphamide instead of
mechlorethamine in MOPP, in combination with
vincristine, procarbazine and prednisone);8,9 69
(52%) received ABVD (doxorubicin, bleomycin,
vinblastine and dacarbazine);10 25 (19%) received
a combination of ABVD and COPP, BEACOPP
(bleomycin, etoposide, doxorubicin, cyclophos-
phamide, vincristine, procarbazine and pred-
nisone) or other mixed COPP and ABVD based
multidrug combination chemotherapy;11,12 and
three patients received other chemotherapeutic
regimens. Forty-nine patients (37%) were treated
with chemotherapy alone, 10 (8%) with radio-
therapy only, and 71 (53%) with combined che-
motherapy and radiotherapy. Three patients died
of comorbidities before any definitive treatment.
Statistical analyses
The χ2 or Fisher’s exact test was used to compare
categorical data. Nonparametric analysis was used
to compare age distribution. Binomial distribu-
tion was used to test the gender distribution in
this area from that reported in Western countries.
Survival curves were generated using the Kaplan–
Meier method and compared using the log-rank
test. Multivariate analyses to clarify the effects of
individual factors were performed with Cox re-
gression. All statistical analyses were performed
using SPSS version 13.0 (SPSS Inc., Chicago, IL,
USA) for Windows, and p values less than 0.05
were considered significant.
Results
Clinical characteristics
The characteristics of the 133 patients are sum-
marized in Table 1. The median age was 26 years
(range, 3–84 years). Young adults younger than
45 years comprised 77% of patients.13 The num-
ber of female and male patients was nearly equal.
The age distribution was similar between males
and females, showing a young-adult mode with
peak incidence around the age of 20 years. The
nodular sclerosis type (NS-HL) was the most
common histopathologic subtype (n = 60, 45%),
followed by mixed cellularity type (MC-HL, 29%),
lymphocyte predominant type (LP-HL, 13%) and
lymphocyte depleted type (LD-HL, 2%). About
half of patients had localized diseases (stage I
and II), and around one third each presented
with B symptoms and bulky tumor, respectively.
Although the International Prognostic Score (IPS)
was initially developed and validated in advanced
HL,13 we tried to apply the score system to the
whole cohort for risk stratification. Of the 99 HL
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patients with adequate data to be rated, more
than two thirds had scores ≤ 2.
The characteristics were further analyzed ac-
cording to the histologic types of HL. There were
significant differences among the four groups of
patients with regard to gender, presentation of
bulky tumor or B symptoms, location of primary
lesions and IPS (Table 2). In contrast to LP-HL,
MC-HL and LD-HL, NS-HL occurred more fre-
quently in females than in males. While 43% of
patients with NS-HL and 32% of those with MC-
HL had bulky tumors, none of the patients with
LP-HL did. Most LP-HL and MC-HL patients pre-
sented with cervical lymphadenopathy, compared
with NS-HL patients in whom involvement of cer-
vical lymph node and mediastinum was almost
equal. Patients with LP-HL had a higher frequency
of lower IPS score than other patients.
Outcomes
The overall complete remission (CR) rate was
87% and the overall survival (OS) rate at 10 years
was 79% after a median follow-up time of 
78 months (range, 1–295 months; Figure 1). As
summarized in Table 3, the variables that were
associated with a higher CR rate included age
younger than 45 years, earlier disease stage, ab-
sence of B symptoms or marrow involvement,
and low IPS. These factors were also associated
with higher OS rate at 10 years. In addition, his-
tologic type and gender, although having no 
significant association with CR rate, was closely
associated with OS rate. Female patients and pa-
tients with LP-HL and NS-HL had a higher OS
rate than male patients and patients with MC-
HL, LD-HL and unclassified HL. The OS rate of
patients who obtained CR after initial definitive
therapy was excellent, but none of the patients
who failed to achieve CR after front-line therapy
had long-term survival. In the multivariate
analysis, the achievement of CR was the only in-
dependent factor to be associated with good OS
(Table 3, Figure 2).
In total, 130 patients received definitive ther-
apy. Treatment outcomes according to treatment
modalities are summarized in Table 4. The choice
of modalities (chemotherapy, radiotherapy or che-
motherapy plus radiotherapy) was associated with
CR and OS rates, but the significance was lost if
the analyses were performed separately among
groups of different stages. In patients who had
received chemotherapy as front-line treatment,
ABVD or ABVD-containing regimens were associ-
ated with both higher CR and OS rates.
Of the 18 patients who did not achieve CR,
including the three who died before any definitive
S.J. Wu, et al
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Table 1. Characteristics of 133 patients
n (%)
Age, yr
< 45 103 (77)
≥ 45 30 (23)
Median (range) 26 (3–84)
Gender
Female 62 (47)
Male 71 (53)
Histologic type
LP 17 (13)
NS 60 (45)
MC 38 (29)
LD 3 (2)
Unclassified 15 (11)
Stage
I 15 (11)
II 56 (42)
III 39 (29)
IV 23 (17)
B symptoms (+) 46 (35)
Bulky mass (+) 43 (32)
Primary site
Neck LN 71 (53)
Mediastinum 38 (28)
Other 24 (18)
Organ involved
Spleen 14 (11)
Marrow 8 (6)
Other extranodal 21 (16)
IPS (n = 99)
0–2 68 (69)
3–7 31 (31)
LP = lymphocyte predominant; NS = nodular sclerosis; MC = mixed
cellularity; LD = lymphocyte depleted; LN = lymph node; IPS =
International Prognostic Score.
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treatment, six had NS-HL, eight had MC-HL, and
four had unclassified HL. Two patients were treated
with salvage chemotherapy of ESHAP (etoposide,
corticosteroid, cytarabine and cisplatin) followed
by allogeneic hematopoietic stem cell transplan-
tation (allo-HSCT). Two patients were treated with
COPP plus radiotherapy and ABVD as salvage
chemotherapy, and eight patients died before ad-
ministration of salvage chemotherapy. However,
none of these 12 patients achieved durable re-
mission and survival. Only one patient went into
remission after high dose chemotherapy with 
autologous hematopoietic stem cell transplanta-
tion (auto-HSCT). The remaining two patients
were lost to follow-up soon thereafter.
Among the 115 patients who achieved re-
mission after induction therapy, 21 had disease
relapse at the end of the study, with an overall
cumulative relapse rate of 23% at 10 years
(Figure 3). The median time from diagnosis to
Table 2. Characteristics of 118 patients with different histologic types
LP (n = 17) NS (n = 60) MC (n = 38) LD (n = 3)
p
n (%) n (%) n (%) n (%)
Age, yr
< 45 11 (65) 53 (88) 28 (74) 2 (67) 0.055
≥ 45 6 (35) 7 (11) 10 (26) 1 (33)
Median 41 24 25 27 0.575
Gender 0.001
Female 4 (24) 39 (65) 14 (37) 0
Male 13 (76) 21 (35) 24 (63) 3 (100)
Stage 0.166
I 4 (24) 2 (3) 7 (18) 0
II 7 (41) 29 (48) 14 (37) 1 (33)
III 5 (29) 17 (28) 12 (32) 1 (33)
IV 1 (6) 12 (20) 5 (13) 1 (33)
B symptoms (+) 1 (6) 21 (35) 17 (45) 2 (67) 0.012
Bulky mass (+) 0 26 (43) 12 (32) 1 (33) 0.002
Primary site 0.002
Neck LN 13 (76) 27 (45) 25 (66) 1 (33)
Mediastinum 0 26 (43) 7 (18) 1 (33)
Other 4 (24) 7 (11) 6 (16) 1 (33)
Organ involved
Spleen 0 9 (15) 4 (11) 0 0.386
Marrow 1 (6) 4 (7) 2 (5) 0 1.000
Other extranodal 1 (6) 13 (22) 3 (8) 2 (67) 0.025
IPS (n = 89) 0.025
0–2 11 (92) 33 (73) 20 (69) 0
3–7 1 (8) 12 (27) 9 (31) 3 (100)
LP = lymphocyte predominant; NS = nodular sclerosis; MC = mixed cellularity; LD = lymphocyte depleted; LN = lymph node; IPS =
International Prognostic Score.
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Figure 1. Overall survival of the 133 patients.
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disease relapse of these 21 patients was 30.4
months (range, 8.1–78.1 months). One of them
was lost to follow-up and four died of HL. One
patient received tumor resection only without
any further salvage chemotherapy or radiotherapy
and he remained alive for more than 7 years
thereafter. Four patients died of disease pro-
gression. Among them, only one patient had 
received standard salvage chemotherapy with
COPP, but the response was poor. The other
Table 3. Treatment results according to clinical characteristics
n CR (%)
Univariate 
OS (%)
Univariate Multivariate analysis
analysis p analysis p HR p
All 133 87 79
Gender
Female 62 92 0.126 87 0.044 1
Male 71 82 73 2.009 0.326
Age
< 45 yr 103 91 0.006 83 0.009 1
≥ 45 yr 30 70 65 0.728 0.599
Histology
LP 17 100 0.091 88 0.026 1
NS 60 90 85 0.722 0.792
MC 38 79 72 1.250 0.858
LD 3 100 33 8.416 0.159
Unclassified 15 73 73 – –
Stage
I 15 100 < 0.001 100 0.001 1
II 56 95 84 17,969.693 0.935
III 39 87 78 17,064.883 0.936
IV 23 56 55 6154.430 0.942
Marrow
Involved 8 50 0.012 50 0.001 1
Not involved 125 89 81 3.829 0.200
Extranodal
Involved 21 67 0.009 64 0.090 1
Not involved 112 90 82 0.946 0.955
B symptoms
Positive 46 72 0.001 65 0.001 1
Negative 87 94 86 2.541 0.216
IPS (n = 99)
0–2 68 96 < 0.001 85 < 0.001 1
3–7 31 55 46 1.257 0.781
CR
Yes 115 – – 90 < 0.001 0.038 < 0.001
No* 18 – 0 1
*Three patients died before any treatment. CR = complete remission rate; OS = 10-year overall survival rate; HR = hazard ratio; 
LP = lymphocyte predominant; NS = nodular sclerosis; MC = mixed cellularity; LD = lymphocyte depleted; IPS = International
Prognostic Score.
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three patients had never received standard salvage
chemotherapy due to poor general condition at
disease recurrence and they finally passed away.
The remaining 15 patients achieved a second CR
after salvage therapy that consisted of combined
chemotherapy and radiotherapy in two patients,
chemotherapy alone in 12 patients, and radio-
therapy alone in one. The chemotherapy regi-
mens included ESHAP in seven patients, ABVD or
ABVD-like regimens in four patients, mixed COPP
and ABVD in two patients, and gemcitabine-based
chemotherapy in one patient. Auto-HSCT was
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Figure 2. Overall survival of patients with or without
achievement of first complete remission (CR1).
Table 4. Treatment results in 130 patients according to different treatment modalities
n CR (%) p OS (%) p
All 130 89 80
C/T alone 49 78 0.014 67 0.031
C/T + R/T 71 95 86
R/T alone 10 100 100
Stage I/II 71 96 88
C/T alone 19 90 0.223 86 0.542
C/T + R/T 42 98 84
R/T alone 10 100 100
Stage III/IV 59 80 69
C/T alone 30 70 0.104 57 0.058
C/T + R/T 29 90 86
With C/T 120 88 78
ABVD 69 91 0.024† 84 0.024†
Merged* 25 92 76
COPP 23 70 59
Other 3 100 100
With R/T 81 95 88
IF 59 97 0.355 91 0.739
Mantle 19 90 82
Other 3 100 100
*Includes alternative ABVD/COPP, BEACOPP and other mixed COPP and ABVD based regimens; †comparison among the three 
groups treated with ABVD, merged and COPP, respectively. CR = complete remission rate; OS = 10-year overall survival rate; 
C/T = chemotherapy; R/T = radiotherapy; IF = involved field.
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Figure 3. Cumulative incidence of recurrence of 115 
patients who achieved first complete remission after 
induction chemotherapy.
performed after the achievement of a second CR
in nine patients. All these patients had continuous
second remission with OS of 40–171 months.
Among 94 patients who achieved continuous
CR after initial therapy, six had died at the time
of writing; four died of causes unrelated to HL
(infection in two, coronary heart disease in one
and flare up of hepatitis B in one), one died of
lung cancer 10 years after HL diagnosis, and one
died of cytomegalovirus disease after auto-HSCT.
The two patients who had died of coronary heart
disease and lung cancer had received radiother-
apy at the neck and mediastinum. Another patient
had colon cancer 10 years after therapy for HL, but
he was alive without HL and colon cancer at his
last follow-up.
Discussion
It is known that the incidence of HL is much
lower in Asia than in the West.14 However, reports
concerning the clinical characteristics and treat-
ment outcomes of HL in Asians are limited and the
number of patients studied was small.15–17 From
our analysis, there are some characteristic features
of HL in Taiwan. The proportion of NS-HL among
total HL was lower in Taiwan than in the West
(45% in Taiwan vs. approximately 70% in the
West) but was comparable to that in Hong Kong
(38%).18,19 Similar differences in the distribution
of histopathologic subtypes of non-HL between
Taiwan and Western countries have also been
previously reported.20,21 Furthermore, while most
patients with LP-HL, MC-HL and LD-HL are
males in Taiwan, as in Western countries, patients
with NS-HL are predominantly females, with a
female to male ratio of nearly 2:1 in Taiwan,
compared to a ratio of approximately 1:1 in 
the West (p = 0.014).19 These differences between
this area and the West might be explained by
both racial and environmental differences in the
pathogenesis of HL in various geographic areas.4,18
Further countrywide epidemiologic studies of
HL in Taiwan are warranted to clarify these
points.
Aside from these features, the other clinical
characteristics of HL in this area are not much
different from those in the West,19 suggesting
that after the development of HL, the disease 
nature and progression are similar among differ-
ent areas. This is reflected in the treatment results. 
A high cure rate of patients with HL was demon-
strated in this study. Although the choice of
treatment modalities (radiotherapy, chemother-
apy alone, or in combination) seemed to be as-
sociated with outcomes, the association became
insignificant after stage stratification because the
clinical stage would influence the treatment plans
for the patients. On the other hand, induction
chemotherapy with ABVD-containing regimen
resulted in better outcome than other regimens.
This result is compatible with the current concept
that ABVD is the first-line chemotherapy regimen
for treating HL.22–25
The standard of salvage therapy for patients
with relapsed HL is still controversial, especially
the timing of auto-HSCT in relapsed HL. In a
large randomized clinical trial, auto-HSCT im-
proved relapse-free survival but failed to improve
OS.26 Conventional salvage chemotherapy, ra-
diotherapy and auto-HSCT were used as salvage
therapy in our cohort, and all led to satisfactory
results. So the treatment of choice remains to be
determined. However, auto-HSCT in our series,
although only performed in a limited number of
patients, revealed good results without excess of
toxicity, suggesting the feasibility, efficacy and
tolerability of this treatment. Auto-HSCT should
thus be one of the rational options of salvage
treatment. However, the outcomes of those who
had refractory diseases, either primary or chemo-
resistant at relapse, were extremely poor. Although
successful treatment of HL by allo-HSCT has been
reported,27 no patients in our cohort survived
after allo-HSCT, which was comparable to the
poor experience with conventional allo-HSCT for
HL in the West.28 Recently, there have been prom-
ising preliminary results of reduced-intensity or
non-myeloablative allo-HSCT in treating relapsed
or refractory HL, which are worthy of further 
investigation.29,30
S.J. Wu, et al
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Another important issue in treating this highly
curative disease is the development of secondary
malignancies or heart diseases in long-term 
follow-up.22,23,25,31 Rare cases, surprisingly, were
discovered on chart review that had secondary
malignancies or heart diseases. However, due to
the rarity of such patients as well as inadequate
duration of follow-up, it is too early to make a
conclusion at present. The long-term toxic effects
of radiotherapy and chemotherapy for HL in
Asians remain to be investigated.
In our analysis, the relevant factors that were
associated with outcomes in HL were similar to
those reported previously.13,32 Surely, many of
these factors are intercorrelated and, due to the
small patient number, we are not willing to set a
distinct prognostic model by analysis of our co-
hort. But an interesting finding was that IPS was
able to stratify all HL patients, not only those
with an advanced stage of the disease. Because
the scoring system was initially validated in ad-
vanced HL by the International Prognostic Factor
Project,13 its applicability to all patient groups
remained unclear. In our analysis, IPS correlated
with outcomes in the whole patient group, sug-
gesting its feasibility for generalized usage. This is
worthy of further validation by large studies.
References
1. Diehl V, Sextro M, Franklin J, et al. Clinical presentation,
course, and prognostic factors in lymphocyte-predominant
Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s
disease: report from the European Task Force on Lymphoma
Project on Lymphocyte-Predominant Hodgkin’s Disease. 
J Clin Oncol 1999;17:776–83.
2. Diehl V, Franklin J, Sextro M, et al. Clinical presentation
and treatment of lymphocyte predominant Hodgkin’s 
disease. In: Mauch PM, Armitage JO, Diehl V, et al, eds.
Hodgkin’s Disease. Philadelphia: Lippincott Williams &
Wilkins, 1999:563.
3. Clarke CA, Glaser SL, Keegan TH, et al. Neighborhood 
socioeconomic status and Hodgkin’s lymphoma incidence
in California. Cancer Epidemiol Biomarkers Prev 2005;14:
1441–7.
4. Glaser SL, Hsu JL. Hodgkin’s disease in Asians. Incidence
patterns and risk factors in population-based data. Leuk
Res 2002;26:261–9.
5. Shimizu H, Tajima K, Kuroishi T, et al. Geographic variation
of Hodgkin’s disease in Japan. Nagoya J Med Sci 1981;
43:101–10.
6. Lukes RJ, Butler JJ. The pathology and nomenclature of
Hodgkin’s disease. Cancer Res 1966;26:1063–83.
7. Lister TA, Crowther D. Staging for Hodgkin’s disease.
Semin Oncol 1990;17:696–703.
8. Blasinska-Morawiec M, Pluzanska A, Krykowski E, et al.
Late results of the treatment of advanced Hodgkin’s 
disease by the MOPP/COPP programs (chlormethine or
cyclophosphamide, vincristine, procarbazine and pred-
nisone). Pol Arch Med Wewn 1991;86:274–80.
9. Morgenfeld MC, Pavlovsky A, Suarez A, et al. Combined
cyclophosphamide, vincristine, procarbazine, and pred-
nisone (COPP) therapy of malignant lymphoma. Evaluation
of 190 patients. Cancer 1975;36:1241–9.
10. Bonadonna G, Santoro A, Gianni AM, et al. Primary and
salvage chemotherapy in advanced Hodgkin’s disease: 
the Milan Cancer Institute experience. Ann Oncol 1991;
2:9–16.
11. Diehl V, Pfreundschuh M, Loffler M, et al. Chemotherapy
of Hodgkin’s lymphoma with alternating cycles of COPP
(cyclophosphamide, vincristin, procarbazine, prednisone)
and ABVD (doxorubicin, bleomycin, vinblastine and
dacarbazine). Results of the HD1 and HD3 trials of the
German Hodgkin Study Group. Med Oncol Tumor
Pharmacother 1989;6:155–62.
12. Ruffer JU, Ballova V, Glossmann J, et al. BEACOPP and
COPP/ABVD as salvage treatment after primary extended
field radiation therapy of early stage Hodgkin’s disease—
results of the German Hodgkin Study Group. Leuk
Lymphoma 2005;46:1561–7.
13. Hasenclever D, Diehl V. A prognostic score for advanced
Hodgkin’s disease. International Prognostic Factors Project
on Advanced Hodgkin’s Disease. N Engl J Med 1998;339:
1506–14.
14. Mueller NE, Grufferman S. The epidemiology of Hodgkin’s
disease. In: Mauch PM, Armitage JO, Diehl V, et al, eds.
Hodgkin’s Disease. Philadelphia: Lippincott Williams &
Wilkins, 1999:61.
15. Liang R, Choi P, Todd D, et al. Hodgkin’s disease in Hong
Kong Chinese. Hematol Oncol 1989;7:395–403.
16. Paulino AF, Paulino-Cabrera E, Weiss LM, et al. Hodgkin’s
disease in the Philippines. Mod Pathol 1996;9:115–9.
17. Zhou XG, Hamilton-Dutoit SJ, Yan QH, et al. The associa-
tion between Epstein-Barr virus and Chinese Hodgkin’s
disease. Int J Cancer 1993;55:359–63.
18. Au WY, Gascoyne RD, Gallagher RE, et al. Hodgkin’s 
lymphoma in Chinese migrants to British Columbia: 
a 25-year survey. Ann Oncol 2004;15:626–30.
19. Stein H, Delsol G, Pileri S, et al. Classical Hodgkin’s lym-
phoma. In: World Health Organization Classification of
Tumours: Tumours of Haematopoietic and Lymphoid
Tissues. Lyon: IARC, 2001.
S.J. Wu, et al
12 J Formos Med Assoc | 2008 • Vol 107 • No 1
20. Shih LY, Liang DC. Non-Hodgkin’s lymphomas in Asia.
Hematol Oncol Clin North Am 1991;5:983–1001.
21. Chen CY, Yao M, Tang JL, et al. Chromosomal abnormali-
ties of 200 Chinese patients with non-Hodgkin’s lymphoma
in Taiwan: with special reference to T-cell lymphoma. 
Ann Oncol 2004;15:1091–6.
22. Thomas RK, Re D, Wolf J, et al. Part I: Hodgkin’s 
lymphoma—molecular biology of Hodgkin and Reed-
Sternberg cells. Lancet Oncol 2004;5:11–8.
23. Diehl V, Thomas RK, Re D. Part II. Hodgkin’s 
lymphoma—diagnosis and treatment. Lancet Oncol
2004;5:19–26.
24. Koontz BF, Kirkpatrick JP, Clough RW, et al. Combined-
modality therapy versus radiotherapy alone for treatment
of early-stage Hodgkin’s disease: cure balanced against
complications. J Clin Oncol 2006;24:605–11.
25. Chow LM, Nathan PC, Hodgson DC, et al. Survival and
late effects in children with Hodgkin’s lymphoma treated
with MOPP/ABV and low-dose, extended-field irradiation.
J Clin Oncol 2006;24:5735–41.
26. Byrne BJ, Gockerman JP. Salvage Therapy in Hodgkin’s
Lymphoma. Oncologist 2007;12:156–67.
27. Murphy F, Sirohi B, Cunningham D. Stem cell transplanta-
tion in Hodgkin’s lymphoma. Exp Rev Anticancer Ther
2007;7:297–306.
28. Schmitz N, Sureda A. The role of allogeneic stem-cell
transplantation in Hodgkin’s disease. Eur J Haematol
2005;Suppl:146–9.
29. Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloabla-
tive stem cell transplantation is an effective therapy for 
refractory or relapsed Hodgkin’s lymphoma: results of 
a Spanish prospective cooperative protocol. Biol Blood
Marrow Transplant 2006;12:172–83.
30. Anderlini P, Champlin RE. Reduced intensity conditioning
for allogeneic stem cell transplantation in relapsed and 
refractory Hodgkin’s lymphoma: where do we stand? Biol
Blood Marrow Transplant 2006;12:599–602.
31. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial 
infarction mortality risk after treatment for Hodgkin’s 
disease: a collaborative British cohort study. J Natl Cancer
Inst 2007;99:206–14.
32. Josting A, Wolf J, Diehl V. Hodgkin’s disease: prognostic
factors and treatment strategies. Curr Opin Oncol 2000;
12:403–11.
